Cardiovascular Systems Inc

Cardiovascular Systems Inc

  • Price (USD)34.53
  • Today's Change-0.935 / -2.64%
  • Shares traded100.41k
  • 1 Year change-9.44%
  • Beta0.8490
Data delayed at least 15 minutes, as of May 10 2021 19:06 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Cardiovascular Systems, Inc. is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary artery diseases, including those with arterial calcium. The Company develops an orbital atherectomy technology for both peripheral and coronary commercial applications. Its peripheral artery disease (PAD) systems are catheter-based platforms capable of treating a range of plaque types in leg arteries both above and below the knee. Its products include Diamondback 360 Peripheral Orbital Atherectomy System (OAS) (Diamondback 360 Peripheral), the Stealth 360 OAS (Stealth 360), Diamondback 360 Peripheral, Diamondback 360 60cm Peripheral, Diamondback 360 Low Profile Peripheral, Diamondback 360 1.50 Peripheral and Diamondback 360 2.00 Peripheral. The Company's coronary arterial disease (CAD) product, Diamondback 360 Coronary OAS (Coronary OAS), is marketed as a treatment for severely calcified coronary arteries.

  • Revenue in USD (TTM)230.53m
  • Net income in USD-23.30m
  • Incorporated2000
  • Employees779.00
  • Location
    Cardiovascular Systems Inc1225 Old Highway 8 NWST. PAUL 55112-6416United StatesUSA
  • Phone+1 (651) 259-1600
  • Fax+1 (612) 677-3355
  • Websitehttp://csi360.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
SI-Bone Inc77.01m-43.17m1.08bn295.00--6.66--13.99-1.42-1.422.534.930.40151.406.86261,044.10-22.51-31.12-24.72-35.6888.0989.24-56.06-50.0414.64-10.140.1965--9.0412.25-13.79--2.73--
Tactile Systems Technology Inc186.23m-1.58m1.10bn707.00--8.78966.305.90-0.0869-0.08699.546.371.134.545.26263,404.50-0.95475.11-1.146.0845.8249.50-0.84793.773.59--0.000.00-1.2524.38-105.65--30.09--
MiMedx Group Inc246.47m-88.36m1.11bn735.00------4.51-0.8141-0.81412.270.75241.413.747.32335,326.50-30.22-6.69-45.83-10.4584.2087.36-21.44-3.572.501.930.3636---17.055.80-225.75---7.37--
Atrion Corporation147.59m32.12m1.14bn636.0035.904.7526.147.7517.4417.4480.17131.680.55811.768.35232,059.8012.1414.9712.7415.7144.8346.5721.7621.994.55--0.0029.22-4.820.2537-12.602.1118.6114.87
Vuzix Corp11.58m-20.01m1.19bn99.00--17.78--102.49-0.5357-0.53570.3041.060.28631.648.39116,984.90-44.37-70.70-47.75-81.4516.64-7.50-155.01-309.2712.58-711.760.00--73.6233.3229.57---6.55--
Cryolife Inc257.89m-13.07m1.20bn1.20k--4.03138.344.65-0.3423-0.34236.757.600.36431.355.31214,904.20-1.86-0.1545-2.00-0.167166.4866.36-5.10-0.34142.800.81660.5158---8.3211.66-1,167.03--12.30--
Orthopediatrics Corp76.18m-38.38m1.26bn116.00--5.68--16.56-2.05-2.054.0611.300.31250.34354.97656,758.60-15.74-12.55-17.56-14.0077.6375.02-50.38-25.752.64-1.830.0051---2.0318.05-159.71--38.07--
Nano-X Imaging Ltd0.00-43.82m1.38bn40.00--5.81-----1.01-
Cardiovascular Systems Inc230.53m-23.30m1.43bn779.00--5.27--6.18-0.6425-0.64256.096.730.81321.766.69295,933.30-8.22-8.25-9.99-10.1978.0380.57-10.11-7.714.99-13.960.071---4.635.44-10,580.78---28.11--
Alphatec Holdings Inc144.86m-78.99m1.47bn296.00--7.14--10.12-1.26-1.262.302.500.67191.057.30489,395.30-36.64-28.67-46.95-43.1270.7667.78-54.53-34.192.37-15.200.2158--27.711.51-38.82--13.56--
Lantheus Holdings Inc341.22m-7.80m1.48bn595.00--2.8169.684.35-0.1761-0.17615.587.830.5476.216.57573,470.60-1.256.05-1.396.9644.3747.97-2.297.432.140.90520.2560.00-2.282.95-142.55---1.05--
Inogen Inc306.93m-4.97m1.49bn938.00--4.19124.514.86-0.2265-0.226513.8815.920.65615.237.79327,217.50-1.067.15-1.218.1145.5147.76-1.627.845.11--0.000.00-14.7714.17-127.82--50.85--
Pulmonx Corp33.36m-37.11m1.52bn170.00--7.01--45.52-1.71-1.711.166.07------196,229.40--------66.44---111.25--16.22-15.580.0741--0.4234---55.68------
Eargo Inc69.15m-30.02m1.58bn238.00--8.14--22.85-0.5217-0.52170.99215.070.53217.7923.67290,563.00-30.67---37.26--68.37---57.63--9.26-18.520.0711--110.90--32.11------
Establishment Labs Holdings Inc90.53m-27.31m1.70bn521.00--23.41--18.73-1.16-1.163.833.060.56451.403.99173,763.90-17.03---19.97--63.0959.08-30.17-53.264.27-4.630.4095---5.4654.580.076------
Luminex Corporation417.40m14.87m1.74bn1.33k114.233.2538.204.180.32270.32279.0711.330.60971.696.80315,015.802.222.762.483.0559.3861.083.634.404.413.140.281872.8624.7311.92243.38-16.60-1.75--
Data as of May 10 2021. Currency figures normalised to Cardiovascular Systems Inc's reporting currency: US Dollar USD

Institutional shareholders

61.46%Per cent of shares held by top holders
HolderShares% Held
BlackRock Fund Advisorsas of 31 Dec 20206.10m15.18%
Brown Capital Management LLCas of 31 Dec 20205.99m14.91%
Champlain Investment Partners LLCas of 31 Dec 20203.07m7.64%
The Vanguard Group, Inc.as of 31 Dec 20202.40m5.96%
SSgA Funds Management, Inc.as of 31 Dec 20201.44m3.59%
Janus Capital Management LLCas of 31 Dec 20201.37m3.41%
Renaissance Technologies LLCas of 31 Dec 20201.28m3.19%
RGM Capital LLCas of 31 Dec 20201.17m2.92%
Wellington Management Co. LLPas of 31 Dec 20201.09m2.70%
New York State Common Retirement Fundas of 31 Dec 2020789.50k1.96%
More ▼
Data from 31 Dec 2020 - 31 Dec 2020Source: FactSet Research Systems Inc.
Refinitiv, an LSEG business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.